#BEGIN_DRUGCARD DB04178

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C44H89NO8P

# Chemical_IUPAC_Name:
[(2S)-2,3-bis(octadecanoyloxy)propoxy][2-(trimethylazaniumyl)ethoxy]phosphinic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Di-Stearoyl-3-Sn-Phosphatidylcholine

# HET_ID:
PC2

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C44H88NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h42H,6-41H2,1-5H3/p+1/t42-/m0/s1

# InChI_Key:
InChIKey=NRJAVPSFFCBXDT-WBCKFURZSA-O

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4178

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
791.1531

# Molecular_Weight_Mono:
790.632580341

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1EWF

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
5.83

# Predicted_LogS:
-7.5

# Predicted_Water_Solubility:
2.96e-05 g/l

# Primary_Accession_No:
DB04178

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5313335

# PubChem_Substance_ID:
46507572

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02512

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](CO[P@@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:03 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Note=Membrane-associated in polymorphonuclear Leukocytes (PMN) granules

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
BPI

# Drug_Target_1_GenBank_ID_Gene:
J04739

# Drug_Target_1_GenBank_ID_Protein:
179529

# Drug_Target_1_GeneCard_ID:
BPI

# Drug_Target_1_Gene_Name:
BPI

# Drug_Target_1_Gene_Sequence:
>1464 bp
ATGAGAGAGAACATGGCCAGGGGCCCTTGCAACGCGCCGAGATGGGTGTCCCTGATGGTG
CTCGTCGCCATAGGCACCGCCGTGACAGCGGCCGTCAACCCTGGCGTCGTGGTCAGGATC
TCCCAGAAGGGCCTGGACTACGCCAGCCAGCAGGGGACGGCCGCTCTGCAGAAGGAGCTG
AAGAGGATCAAGATTCCTGACTACTCAGACAGCTTTAAGATCAAGCATCTTGGGAAGGGG
CATTATAGCTTCTACAGCATGGACATCCGTGAATTCCAGCTTCCCAGTTCCCAGATAAGC
ATGGTGCCCAATGTGGGCCTTAAGTTCTCCATCAGCAACGCCAATATCAAGATCAGCGGG
AAATGGAAGGCACAAAAGAGATTCTTAAAAATGAGCGGCAATTTTGACCTGAGCATAGAA
GGCATGTCCATTTCGGCTGATCTGAAGCTGGGCAGTAACCCCACGTCAGGCAAGCCCACC
ATCACCTGCTCCAGCTGCAGCAGCCACATCAACAGTGTCCACGTGCACATCTCAAAGAGC
AAAGTCGGGTGGCTGATCCAACTCTTCCACAAAAAAATTGAGTCTGCGCTTCGAAACAAG
ATGAACAGCCAGGTCTGCGAGAAAGTGACCAATTCTGTATCCTCCAAGCTGCAACCTTAT
TTCCAGACTCTGCCAGTAATGACCAAAATAGATTCTGTGGCTGGAATCAACTATGGTCTG
GTGGCACCTCCAGCAACCACGGCTGAGACCCTGGATGTACAGATGAAGGGGGAGTTTTAC
AGTGAGAACCACCACAATCCACCTCCCTTTGCTCCACCAGTGATGGAGTTTCCCGCTGCC
CATGACCGCATGGTATACCTGGGCCTCTCAGACTACTTCTTCAACACAGCCGGGCTTGTA
TACCAAGAGGCTGGGGTCTTGAAGATGACCCTTAGAGATGACATGATTCCAAAGGAGTCC
AAATTTCGACTGACAACCAAGTTCTTTGGAACCTTCCTACCTGAGGTGGCCAAGAAGTTT
CCCAACATGAAGATACAGATCCATGTCTCAGCCTCCACCCCGCCACACCTGTCTGTGCAG
CCCACCGGCCTTACCTTCTACCCTGCCGTGGATGTCCAGGCCTTTGCCGTCCTCCCCAAC
TCCTCCCTGGCTTCCCTCTTCCTGATTGGCATGCACACAACTGGTTCCATGGAGGTCAGC
GCCGAGTCCAACAGGCTTGTTGGAGAGCTCAAGCTGGATAGGCTGCTCCTGGAACTGAAG
CACTCAAATATTGGCCCCTTCCCGGTTGAATTGCTGCAGGATATCATGAACTACATTGTA
CCCATTCTTGTGCTGCCCAGGGTTAACGAGAAACTACAGAAAGGCTTCCCTCTCCCGACG
CCGGCCAGAGTCCAGCTCTACAACGTAGTGCTTCAGCCTCACCAGAACTTCCTGCTGTTC
GGTGCAGACGTTGTCTATAAATGA

# Drug_Target_1_General_Function:
Involved in lipid binding

# Drug_Target_1_General_References:
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
2501794	Gabay JE, Scott RW, Campanelli D, Griffith J, Wilde C, Marra MN, Seeger M, Nathan CF: Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5610-4.
2722846	Gray PW, Flaggs G, Leong SR, Gumina RJ, Weiss J, Ooi CE, Elsbach P: Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations. J Biol Chem. 1989 Jun 5;264(16):9505-9.
3667613	Ooi CE, Weiss J, Elsbach P, Frangione B, Mannion B: A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J Biol Chem. 1987 Nov 5;262(31):14891-4.
7517398	Wilde CG, Seilhamer JJ, McGrogan M, Ashton N, Snable JL, Lane JC, Leong SR, Thornton MB, Miller KL, Scott RW, et al.: Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein. LPS binding properties and effects on LPS-mediated cell activation. J Biol Chem. 1994 Jul 1;269(26):17411-6.
9188532	Beamer LJ, Carroll SF, Eisenberg D: Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science. 1997 Jun 20;276(5320):1861-4.

# Drug_Target_1_HGNC_ID:
HGNC:1095

# Drug_Target_1_HPRD_ID:
00174

# Drug_Target_1_ID:
1900

# Drug_Target_1_Locus:
20q11.23-q12

# Drug_Target_1_Molecular_Weight:
53397

# Drug_Target_1_Name:
Bactericidal permeability-increasing protein

# Drug_Target_1_Number_of_Residues:
483

# Drug_Target_1_PDB_ID:
1BP1

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01273	LBP_BPI_CETP
PF02886	LBP_BPI_CETP_C

# Drug_Target_1_Protein_Sequence:
>Bactericidal permeability-increasing protein precursor
MARGPCNAPRWVSLMVLVAIGTAVTAAVNPGVVVRISQKGLDYASQQGTAALQKELKRIK
IPDYSDSFKIKHLGKGHYSFYSMDIREFQLPSSQISMVPNVGLKFSISNANIKISGKWKA
QKRFLKMSGNFDLSIEGMSISADLKLGSNPTSGKPTITCSSCSSHINSVHVHISKSKVGW
LIQLFHKKIESALRNKMNSQVCEKVTNSVSSKLQPYFQTLPVMTKIDSVAGINYGLVAPP
ATTAETLDVQMKGEFYSENHHNPPPFAPPVMEFPAAHDRMVYLGLSDYFFNTAGLVYQEA
GVLKMTLRDDMIPKESKFRLTTKFFGTFLPEVAKKFPNMKIQIHVSASTPPHLSVQPTGL
TFYPAVDVQAFAVLPNSSLASLFLIGMHTTGSMEVSAESNRLVGELKLDRLLLELKHSNI
GPFPVELLQDIMNYIVPILVLPRVNEKLQKGFPLPTPARVQLYNVVLQPHQNFLLFGADV
VYK

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-27

# Drug_Target_1_Specific_Function:
The cytotoxic action of BPI is limited to many species of Gram-negative bacteria; this specificity may be explained by a strong affinity of the very basic N-terminal half for the negatively charged lipopolysaccharides that are unique to the Gram-negative bacterial outer envelope

# Drug_Target_1_SwissProt_ID:
P17213

# Drug_Target_1_SwissProt_Name:
BPI_HUMAN

# Drug_Target_1_Synonyms:
BPI
Bactericidal permeability-increasing protein precursor
CAP 57

# Drug_Target_1_Theoretical_pI:
10.00

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Mitochondrion
mitochondrial inner membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
SLC25A4

# Drug_Target_2_GenBank_ID_Gene:
J02966

# Drug_Target_2_GenBank_ID_Protein:
339920

# Drug_Target_2_GeneCard_ID:
SLC25A4

# Drug_Target_2_Gene_Name:
SLC25A4

# Drug_Target_2_Gene_Sequence:
>894 bp
ATGGGTGATCACGCTTGGAGCTTCCTAAAGGACTTCCTGGCCGGGGCGGTCGCCGCTGCC
GTCTCCAAGACCGCGGTCGCCCCCATCGAGAGGGTCAAACTGCTGCTGCAGGTCCAGCAT
GCCAGCAAACAGATCAGTGCTGAGAAGCAGTACAAAGGGATCATTGATTGTGTGGTGAGA
ATCCCTAAGGAGCAGGGCTTCCTCTCCTTCTGGAGGGGTAACCTGGCCAACGTGATCCGT
TACTTCCCCACCCAAGCTCTCAACTTCGCCTTCAAGGACAAGTACAAGCAGCTCTTCTTA
GGGGGTGTGGATCGGCATAAGCAGTTCTGGCGCTACTTTGCTGGTAACCTGGCGTCCGGT
GGGGCCGCTGGGGCCACCTCCCTTTGCTTTGTCTACCCGCTGGACTTTGCTAGGACCAGG
TTGGCTGCTGATGTGGGCAGGCGCGCCCAGCGTGAGTTCCATGGTCTGGGCGACTGTATC
ATCAAGATCTTCAAGTCTGATGGCCTGAGGGGGCTCTACCAGGGTTTCAACGTCTCTGTC
CAAGGCATCATTATCTATAGAGCTGCCTACTTCGGAGTCTATGATACTGCCAAGGGGATG
CTGCCTGACCCCAAGAACGTGCACATTTTTGTGAGCTGGATGATTGCCCAGAGTGTGACG
GCAGTCGCAGGGCTGCTGTCCTACCCCTTTGACACTGTTCGTCGTAGAATGATGATGCAG
TCCGGCCGGAAAGGGGCCGATATTATGTACACGGGGACAGTTGACTGCTGGAGGAAGATT
GCAAAAGACGAAGGAGCCAAGGCCTTCTTCAAAGGTGCCTGGTCCAATGTGCTGAGAGGC
ATGGGCGGTGCTTTTGTATTGGTGTTGTATGATGAGATCAAAAAATATGTCTAA

# Drug_Target_2_General_Function:
Involved in nucleotide transporter activity

# Drug_Target_2_General_References:
10926541	Kaukonen J, Juselius JK, Tiranti V, Kyttala A, Zeviani M, Comi GP, Keranen S, Peltonen L, Suomalainen A: Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science. 2000 Aug 4;289(5480):782-5.
11756613	Napoli L, Bordoni A, Zeviani M, Hadjigeorgiou GM, Sciacco M, Tiranti V, Terentiou A, Moggio M, Papadimitriou A, Scarlato G, Comi GP: A novel missense adenine nucleotide translocator-1 gene mutation in a Greek adPEO family. Neurology. 2001 Dec 26;57(12):2295-8.
12112115	Komaki H, Fukazawa T, Houzen H, Yoshida K, Nonaka I, Goto Y: A novel D104G mutation in the adenine nucleotide translocator 1 gene in autosomal dominant progressive external ophthalmoplegia patients with mitochondrial DNA with multiple deletions. Ann Neurol. 2002 May;51(5):645-8.
2541251	Cozens AL, Runswick MJ, Walker JE: DNA sequences of two expressed nuclear genes for human mitochondrial ADP/ATP translocase. J Mol Biol. 1989 Mar 20;206(2):261-80.
2547778	Li K, Warner CK, Hodge JA, Minoshima S, Kudoh J, Fukuyama R, Maekawa M, Shimizu Y, Shimizu N, Wallace DC: A human muscle adenine nucleotide translocator gene has four exons, is located on chromosome 4, and is differentially expressed. J Biol Chem. 1989 Aug 25;264(24):13998-4004.
2823266	Neckelmann N, Li K, Wade RP, Shuster R, Wallace DC: cDNA sequence of a human skeletal muscle ADP/ATP translocator: lack of a leader peptide, divergence from a fibroblast translocator cDNA, and coevolution with mitochondrial DNA genes. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7580-4.
2829183	Houldsworth J, Attardi G: Two distinct genes for ADP/ATP translocase are expressed at the mRNA level in adult human liver. Proc Natl Acad Sci U S A. 1988 Jan;85(2):377-81.

# Drug_Target_2_HGNC_ID:
HGNC:10990

# Drug_Target_2_HPRD_ID:
00058

# Drug_Target_2_ID:
661

# Drug_Target_2_Locus:
4q35

# Drug_Target_2_Molecular_Weight:
32934

# Drug_Target_2_Name:
ADP/ATP translocase 1

# Drug_Target_2_Number_of_Residues:
297

# Drug_Target_2_PDB_ID:
1OKC

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00153	Mito_carr

# Drug_Target_2_Protein_Sequence:
>ADP/ATP translocase 1
GDHAWSFLKDFLAGGVAAAVSKTAVAPIERVKLLLQVQHASKQISAEKQYKGIIDCVVRI
PKEQGFLSFWRGNLANVIRYFPTQALNFAFKDKYKQLFLGGVDRHKQFWRYFAGNLASGG
AAGATSLCFVYPLDFARTRLAADVGKGAAQREFHGLGDCIIKIFKSDGLRGLYQGFNVSV
QGIIIYRAAYFGVYDTAKGMLPDPKNVHIFVSWMIAQSVTAVAGLVSYPFDTVRRRMMMQ
SGRKGADIMYTGTVDCWRKIAKDEGAKAFFKGAWSNVLRGMGGAFVLVLYDEIKKYV

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes the exchange of ADP and ATP across the mitochondrial inner membrane

# Drug_Target_2_SwissProt_ID:
P12235

# Drug_Target_2_SwissProt_Name:
ADT1_HUMAN

# Drug_Target_2_Synonyms:
ADP,ATP carrier protein 1
ADP,ATP carrier protein, heart/skeletal muscle isoform T1
ANT 1
Adenine nucleotide translocator 1
Solute carrier family 25 member 4

# Drug_Target_2_Theoretical_pI:
10.27

# Drug_Target_2_Transmembrane_Regions:
4-38
74-99
108-142
175-201
206-240
272-297

#END_DRUGCARD DB04178
